» Articles » PMID: 31077688

Surgical Management of Diabetic Tractional Retinal Detachments

Overview
Journal Surv Ophthalmol
Specialty Ophthalmology
Date 2019 May 12
PMID 31077688
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Tractional retinal detachment is an end-stage form of diabetic retinopathy that occurs when contractile forces in the vitreous and neovascular tissue lead to the detachment of the neurosensory retina. We review the literature related to the management of this disease. Preoperative planning includes appropriate patient selection, diagnostic and prognostic imaging, and medical optimization with reduction of systemic risk factors. Use of antivascular endothelial growth factor for preoperative treatment has had significant benefits for tractional retinal detachment repair in improving surgical efficiency and outcomes. Advances in microsurgical instrumentation are discussed, with attention to small-gauge vitrectomy with improved flow dynamics, viewing strategies, and lighting allowing bimanual surgery. Special emphasis is placed on bimanual surgical technique, choice of tamponade, and the avoidance of iatrogenic damage. Complications and special considerations are further explored. Based on our compilation of relevant literature, we propose a surgical algorithm for the management of these complex patients.

Citing Articles

Ultra-wide-field imaging of proliferative diabetic retinopathy with macular tractional retinal detachment and florid neovascularization.

Mishra C, Kannan N Eye (Lond). 2025; .

PMID: 39910279 DOI: 10.1038/s41433-025-03663-y.


Elucidating postoperative dynamics in tractional retinal detachment: a systematic review and meta-analysis of structural and functional outcomes following diabetic vitrectomy, including an analysis of postoperative complications.

Quiroz-Reyes M, Quiroz-Gonzalez E, Quiroz-Gonzalez M, Lima-Gomez V BMC Ophthalmol. 2024; 24(1):547.

PMID: 39719566 PMC: 11668018. DOI: 10.1186/s12886-024-03820-z.


Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off, Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage.

Yuan M, Hoyek S, Kim L, Chaaya C, Patel N J Vitreoretin Dis. 2024; :24741264241297684.

PMID: 39544710 PMC: 11558646. DOI: 10.1177/24741264241297684.


Intraoperative challenges and management of fibrovascular membrane with tractional retinoschisis in proliferative diabetic retinopathy.

Shiraki A, Shiraki N, Sakimoto S, Maruyama K, Maeno T, Nishida K BMC Ophthalmol. 2024; 24(1):299.

PMID: 39033302 PMC: 11264879. DOI: 10.1186/s12886-024-03555-x.


Exploration of potential novel drug targets for diabetic retinopathy by plasma proteome screening.

Yuan W, Xu W, Xu X, Qu B, Zhao F Sci Rep. 2024; 14(1):11726.

PMID: 38778174 PMC: 11111739. DOI: 10.1038/s41598-024-62069-0.